We evaluated the therapeutic potential of silencing sortilin expression in vivo using antisense oligonucleotide (ASO-Sort1) to reduce atherosclerosis and associated calcification. Male and female Ldl (low-density lipoprotein) receptor deficient mice were fed a high-fat diet and treated with ASO-Sort1 for 15 weeks.